Pascal Biosciences Inc. (PAS.V)
| Previous Close | 0.0850 |
| Open | 0.0850 |
| Bid | 0.0850 x N/A |
| Ask | 0.0900 x N/A |
| Day's Range | 0.0850 - 0.0850 |
| 52 Week Range | 0.0800 - 0.2600 |
| Volume | 3,000 |
| Avg. Volume | 53,364 |
| Market Cap | 5.533M |
| Beta (5Y Monthly) | 1.34 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0160 |
| Earnings Date | Apr. 23, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
Hardy Forzley Joins Pascal Biosciences as Chief Financial Officer
VANCOUVER, BC / ACCESSWIRE / June 16, 2021 / Pascal Biosciences Inc. ("Pascal") (TSXV:PAS) (OTC PINK:PSCBF) (FSE:6PB), announced today the appointment of Hardy Forzley as Chief Financial Officer.
- Newsfile
InvestmentPitch Media Video Discusses Pascal Biosciences and its Award of a National Cancer Institute Grant for its Acute Lymphoblastic Leukemia Program - Video Available on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - June 9, 2021) - Pascal Biosciences (TSXV: PAS) (OTC Pink: PSCBF) (FSE: 6PB), a biotechnology company targeting innovative therapies for serious diseases, including COVID-19, has been awarded a grant from the National Cancer Institute of the US National Institutes of Health. This two-year grant of US$343,750 will fund development of Pascal's antibody drug for Acute Lymphoblastic Leukemia or "ALL".For more information, please view the InvestmentPitch
- ACCESSWIRE
Pascal Biosciences Awarded NIH Grant For Leukemia Program
VANCOUVER, BC / ACCESSWIRE / June 8, 2021 / Pascal Biosciences Inc. ("Pascal" or the "Company") (TSXV:PAS)(OTC PINK:PSCBF), has been awarded a grant of US$343,750 from the National Cancer Institute of the US National Institutes of Health (NIH).
